First day of dealings on AIM
1st February 2006
Not for release or distribution or publication in whole or part
in or into the United States, Canada, Japan, Republic of Ireland or
Australia
Intercytex Group plc (“Intercytex” or the
“Company”)
Cambridge, UK, 1 February 2006 - Intercytex
Group plc, a UK-based emerging healthcare company developing cell
therapy products for the woundcare and aesthetic medicine markets,
is pleased to announce that admission to trading on AIM will become
effective, and dealings in the ordinary shares of the Company will
commence, at 8.00am today, Wednesday, 1 February 2006, under the
ticker symbol ICX.L.
Piper Jaffray Ltd. is acting as nominated adviser and sole
broker to the Company.
Enquiries at:
| Intercytex Group plc |
+44 (0)161 904 4500 |
|
Nick Higgins, Chief Executive Officer |
|
| Richard Moulson, Chief Financial Officer |
|
| |
Website:
www.intercytex.com |
| |
|
| Piper Jaffray Ltd. |
+44 (0)20 7743 8700 |
| Jamie Adams |
|
| David Rasouly |
|
| Will Carnwath |
|
| |
|
| Financial Dynamics |
+44 (0)20 7831 3113 |
| David Yates |
|
| Davina Langdale |
|
|
Contact Us
